Therefore, it is rational to assume that the comprehensive and integrated evaluation of genomic (TMB, single gene mutations, MSI etc.)[27], immunohistochemical (e.g. PD-L1 expression) [19, 21] and histological (e.g. tumor grading and tumor infiltrating lymphocytes—TILs) [19] variables can significantly refine the selection of patients candidate for treatment with immune-checkpoints-modulators. This evidence concerns the gene CD274 and neoplasm.